奥美医疗(002950) - 2024 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2024 reached ¥868,422,531.97, representing a 46.80% increase compared to the same period last year[2]. - Net profit attributable to shareholders for Q3 2024 was ¥78,168,683.68, a significant increase of 1,278.25% year-on-year[2]. - The basic earnings per share for Q3 2024 was ¥0.1234, reflecting a 1,275.24% increase compared to the same period last year[2]. - Total operating revenue for Q3 2024 reached CNY 2,450,075,783.88, an increase of 21.4% compared to CNY 2,018,286,601.72 in the same period last year[10]. - Net profit for Q3 2024 was CNY 265,683,777.98, representing a 83.1% increase from CNY 145,096,053.88 in Q3 2023[10]. - Basic and diluted earnings per share for the quarter were both CNY 0.4233, compared to CNY 0.2375 in the previous year[11]. Assets and Liabilities - Total assets at the end of Q3 2024 amounted to ¥5,156,594,798.74, showing a 1.42% increase from the end of the previous year[2]. - The total assets of the company as of the end of Q3 2024 were CNY 5,156,594,798.74, a slight increase from CNY 5,084,318,038.89 at the end of Q3 2023[9]. - Total liabilities decreased to CNY 1,796,282,948.79 from CNY 1,873,358,139.47 year-over-year[9]. - The company's equity attributable to shareholders increased by 4.65% to ¥3,335,462,638.23 compared to the end of the previous year[2]. Cash Flow - The company's cash flow from operating activities for the year-to-date was ¥516,704,451.55, an increase of 12.51% compared to the same period last year[5]. - Operating cash flow for the current period reached ¥516,704,451.55, an increase of 12.5% compared to ¥459,259,090.89 in the previous period[12]. - The company reported a significant increase in cash flow due to reduced loan repayments and higher income[6]. - Cash received from sales of goods and services was ¥2,469,058,605.43, an increase from ¥2,216,900,510.46 in the previous period[12]. - Cash paid for purchasing goods and services was ¥1,603,399,851.55, compared to ¥1,376,936,669.66 in the previous period[12]. - The net increase in cash and cash equivalents for the current period was ¥216,716,227.75, compared to a decrease of -¥109,256,670.08 in the previous period[13]. Expenses - The company reported a 54.63% increase in selling expenses, totaling ¥69,736,169.45, due to increased revenue[5]. - Operating costs for the same period were CNY 2,139,239,584.07, up 18.3% from CNY 1,807,626,230.75 year-over-year[10]. - Research and development expenses for Q3 2024 were CNY 57,853,716.21, a decrease of 3.5% from CNY 60,060,955.75 in the same quarter last year[10]. Shareholder Information - The number of common shareholders reached 41,703 by the end of the reporting period[6]. - The top ten shareholders include major stakeholders such as 崔金海 (23.02%) and 程宏 (15.14%) with significant holdings[6]. - The company held 12,520,110 shares in the repurchase special securities account, representing 1.98% of the total share capital as of September 30, 2024[7]. Future Outlook - The company continues to focus on market expansion and new product development strategies[6]. - The company plans to continue expanding its market presence and investing in new product development to drive future growth[10].